Phytorelief has been developed by AlchemLife and has a US and EU patent granted
AIIMS Patna confirms the efficacy of AlchemLife’s Phytorelief in the management of mild and moderate cases of COVID-19 by acting as a natural anti-viral agent which helps in limiting COVID-19 spread in the initial stages of the disease.
In a recent clinical study conducted by AIIMS Patna, 100 COVID-19 positive cases with mild and moderate symptoms were tested with Phytorelief. It was interesting to note that after ten days of treatment with Phytorelief along with standard management, 83 per cent of COVID-19 patients, with mild or moderate symptoms, turned negative. It was evident from the study that Phytorelief helps in boosting the immunity to fight the virus and in turn, helps in reducing the viral load. All the COVID-19 patients who were treated with Phytorelief recovered well and showed significant improvements in all symptoms of COVID-19 like fever, cough, sore throat, and myalgia.
As Phytorelief pastille is absorbed in the buccal cavity (mouth, saliva), the infection site helps limit the spread of viruses in its early stages.
Phytorelief contains Phytoactives (the most powerful active ingredients in medicinal plants) of curcuminoids in Turmeric, ellagic acid in Pomegranate, and gingerols and shogaols in Ginger. The synergistic effect of these Phytoactives results in a strong anti-viral, virucidal and anti-bacterial action and can be effective against various viral strains.
Phytorelief has been developed by New Delhi-based AlchemLife and has a US and EU patent granted. It has been clinically tested. Various studies conducted on Phytorelief have shown that it is effective in increasing immunity by up to 4 times against viruses that cause cough, cold, and flu. It has already been used to treat cough, cold, and flu symptoms over the years.